New cancer pill begins first human safety tests
NCT ID NCT06943677
Summary
This is the first study in people to test the safety and side effects of a new oral medication called TQB3019 for advanced cancers. Researchers will give the capsules to about 80 adults with advanced cancer to find the safest and most tolerable dose. The main goals are to understand how the body processes the drug and to watch for any serious side effects, while also checking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of North sichuan Medical college
NOT_YET_RECRUITINGNanchong, Sichuan, 637000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Institute & Hospital.Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Heze Municipal Hospital
NOT_YET_RECRUITINGHeze, Shandong, 27400, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institute of Hematology ＆Blood Diseases Hospital,Chinese Academy of Medical Sciences ＆Peking Union Medical College
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 301617, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mianyang Central Hospital
NOT_YET_RECRUITINGMianyang, Sichuan, 621000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanfang Hospital of Southern Medical University
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Qingdao University
NOT_YET_RECRUITINGQingdao, Shandong, 266075, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Southwest Medical University
NOT_YET_RECRUITINGLuzhou, Sichuan, 646099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Cancer Hospital Affiliated to Shandong First Medical University
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, 330006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITINGXi'an, Shaanxi, 710061, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
TianJin Medical University Cancer Institute&Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital of Tongji University
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200065, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.